BNP Paribas Financial Markets Acquires 14,287 Shares of Alector, Inc. (NASDAQ:ALEC)

BNP Paribas Financial Markets grew its stake in shares of Alector, Inc. (NASDAQ:ALECFree Report) by 17.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 94,955 shares of the company’s stock after purchasing an additional 14,287 shares during the quarter. BNP Paribas Financial Markets’ holdings in Alector were worth $758,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ALEC. Principal Financial Group Inc. lifted its position in shares of Alector by 20.2% in the 3rd quarter. Principal Financial Group Inc. now owns 41,493 shares of the company’s stock worth $269,000 after purchasing an additional 6,973 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Alector during the 3rd quarter valued at $1,103,000. Barclays PLC increased its position in shares of Alector by 24.0% during the 3rd quarter. Barclays PLC now owns 138,826 shares of the company’s stock valued at $899,000 after purchasing an additional 26,856 shares during the last quarter. Shell Asset Management Co. bought a new position in Alector in the 3rd quarter worth $204,000. Finally, Rafferty Asset Management LLC raised its stake in Alector by 12.2% during the 3rd quarter. Rafferty Asset Management LLC now owns 186,624 shares of the company’s stock worth $1,209,000 after acquiring an additional 20,328 shares during the period. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Wall Street Analysts Forecast Growth

ALEC has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Alector in a report on Thursday, May 9th. HC Wainwright dropped their target price on Alector from $41.00 to $35.00 and set a “buy” rating for the company in a report on Thursday, May 9th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Alector presently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

View Our Latest Report on Alector

Alector Price Performance

Shares of ALEC opened at $4.92 on Friday. The company has a 50-day moving average of $5.48 and a 200 day moving average of $6.12. Alector, Inc. has a 1-year low of $3.66 and a 1-year high of $9.06. The firm has a market capitalization of $474.21 million, a price-to-earnings ratio of -3.57 and a beta of 0.82.

Alector (NASDAQ:ALECGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.10. Alector had a negative return on equity of 71.80% and a negative net margin of 125.11%. The firm had revenue of $15.89 million during the quarter, compared to the consensus estimate of $14.63 million. On average, equities analysts anticipate that Alector, Inc. will post -1.97 earnings per share for the current fiscal year.

Insider Buying and Selling at Alector

In other news, CFO Marc Grasso sold 5,716 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $6.92, for a total value of $39,554.72. Following the sale, the chief financial officer now directly owns 144,957 shares in the company, valued at approximately $1,003,102.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Alector news, CFO Marc Grasso sold 5,716 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $6.92, for a total value of $39,554.72. Following the completion of the sale, the chief financial officer now owns 144,957 shares of the company’s stock, valued at $1,003,102.44. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Gary Romano sold 6,001 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $41,526.92. Following the transaction, the insider now owns 196,313 shares in the company, valued at approximately $1,358,485.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,554 shares of company stock valued at $211,434. 9.10% of the stock is currently owned by corporate insiders.

About Alector

(Free Report)

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

Featured Articles

Want to see what other hedge funds are holding ALEC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alector, Inc. (NASDAQ:ALECFree Report).

Institutional Ownership by Quarter for Alector (NASDAQ:ALEC)

Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.